PMID- 26202188
OWN - NLM
STAT- MEDLINE
DCOM- 20160412
LR  - 20240109
IS  - 1875-5607 (Electronic)
IS  - 1389-5575 (Linking)
VI  - 15
IP  - 14
DP  - 2015
TI  - Recent Advances in Synthetic Chemistry of Diabetic Research.
PG  - 1159-63
AB  - Diseases started even before the existence of human beings. Therefore, when the 
      civilization began, the biggest threats for human were diseases. Man has made 
      several sincere attempts for the search of new drugs in order to cure and control 
      different diseases. Type 2 diabetes mellitus (T2DM) is a chronic metabolic 
      disorder that accounts for about 85-95% of all diagnosed cases of diabetes. It is 
      characterized by abnormalities in glucose homeostasis in many organs, and is 
      associated with considerable morbidity and mortality. Extensive research has been 
      carried out using rational drug design to identify and optimize new leads for 
      molecular targets of T2DM, which include Heterocyclic compounds, metal complexes, 
      H3 receptor antagonists, glucagon receptor antagonists and human 
      incretin-degrading enzyme dipeptidyl peptidase IV inhibitors.
FAU - Thota, Sreekanth
AU  - Thota S
AD  - National Institute for Science and Technology on Innovation on Neglected 
      Diseases, Center for Technological Development in Health, Oswaldo Cruz Foundation 
      (Fiocruz), Av. Brazil 4036, Manguinhos, 21040-361 - Rio de Janeiro - RJ - Brazil. 
      sthota@cdts.fiocruz.br.
FAU - Morel, Carlos M
AU  - Morel CM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Mini Rev Med Chem
JT  - Mini reviews in medicinal chemistry
JID - 101094212
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Heterocyclic Compounds)
RN  - 0 (Histamine H3 Antagonists)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Organometallic Compounds)
SB  - IM
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/chemical synthesis/chemistry/*therapeutic use
MH  - Drug Design
MH  - Heterocyclic Compounds/chemical synthesis/chemistry/*therapeutic use
MH  - Histamine H3 Antagonists/chemical synthesis/chemistry/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/chemical synthesis/chemistry/*therapeutic use
MH  - Molecular Docking Simulation
MH  - Molecular Structure
MH  - Organometallic Compounds/chemical synthesis/chemistry/*therapeutic use
EDAT- 2015/07/24 06:00
MHDA- 2016/04/14 06:00
CRDT- 2015/07/24 06:00
PHST- 2014/12/15 00:00 [received]
PHST- 2015/04/21 00:00 [revised]
PHST- 2015/07/12 00:00 [accepted]
PHST- 2015/07/24 06:00 [entrez]
PHST- 2015/07/24 06:00 [pubmed]
PHST- 2016/04/14 06:00 [medline]
AID - MRMC-EPUB-68944 [pii]
AID - 10.2174/1389557515666150722112942 [doi]
PST - ppublish
SO  - Mini Rev Med Chem. 2015;15(14):1159-63. doi: 10.2174/1389557515666150722112942.